Anthem Biosciences files DRHP for Rs. 3,395 crore IPO
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
For Q2, Akums reported a consolidated total income of Rs. 1,046.6 crore
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Subscribe To Our Newsletter & Stay Updated